CR20220520A - Crystalline ret inhibitor - Google Patents

Crystalline ret inhibitor

Info

Publication number
CR20220520A
CR20220520A CR20220520A CR20220520A CR20220520A CR 20220520 A CR20220520 A CR 20220520A CR 20220520 A CR20220520 A CR 20220520A CR 20220520 A CR20220520 A CR 20220520A CR 20220520 A CR20220520 A CR 20220520A
Authority
CR
Costa Rica
Prior art keywords
crystalline
ret inhibitor
ret
crystalline form
diseases
Prior art date
Application number
CR20220520A
Other languages
Spanish (es)
Inventor
Jeremy Miles Merritt
Jon Gordon Selbo
Mark Steven Kerr
Douglas Patton Kjell
Shekhar Krishna Viswanath
Rajni Miglani Bhardwaj
Original Assignee
Loxo Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loxo Oncology Inc filed Critical Loxo Oncology Inc
Publication of CR20220520A publication Critical patent/CR20220520A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Semiconductor Lasers (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Provided herein is a crystalline form of selpercatinib useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders, and methods of making this crystalline form.
CR20220520A 2020-04-17 2021-04-09 Crystalline ret inhibitor CR20220520A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063011701P 2020-04-17 2020-04-17
US202163151354P 2021-02-19 2021-02-19
PCT/US2021/026611 WO2021211380A1 (en) 2020-04-17 2021-04-09 Crystalline ret inhibitor

Publications (1)

Publication Number Publication Date
CR20220520A true CR20220520A (en) 2022-11-15

Family

ID=75747118

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220520A CR20220520A (en) 2020-04-17 2021-04-09 Crystalline ret inhibitor

Country Status (17)

Country Link
EP (1) EP4136090A1 (en)
JP (1) JP2023522012A (en)
KR (1) KR20230002706A (en)
CN (1) CN115916791A (en)
AU (1) AU2021255488B2 (en)
BR (1) BR112022020446A2 (en)
CA (1) CA3174316A1 (en)
CL (1) CL2022002849A1 (en)
CO (1) CO2022014882A2 (en)
CR (1) CR20220520A (en)
DO (1) DOP2022000221A (en)
EC (1) ECSP22080982A (en)
IL (1) IL297212A (en)
MX (1) MX2022012952A (en)
PE (1) PE20230388A1 (en)
TW (1) TW202202501A (en)
WO (1) WO2021211380A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022069357A1 (en) * 2020-10-01 2022-04-07 Sandoz Ag Crystalline form of selpercatinib
US20230183266A1 (en) 2021-12-13 2023-06-15 Loxo Oncology, Inc. Crystalline forms of ret inhibitor and preparation thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI704148B (en) * 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TWI812649B (en) * 2017-10-10 2023-08-21 美商絡速藥業公司 Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
TWI791053B (en) * 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof
TWI783057B (en) 2017-10-10 2022-11-11 美商絡速藥業公司 Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
CN114380825B (en) * 2018-09-30 2024-02-13 北京志健金瑞生物医药科技有限公司 Substituted pyrazole condensed ring derivative and preparation method and application thereof
CN111004257B (en) * 2019-12-24 2021-06-29 武汉九州钰民医药科技有限公司 Method for preparing RET inhibitor Selpercatinib

Also Published As

Publication number Publication date
JP2023522012A (en) 2023-05-26
BR112022020446A2 (en) 2022-11-29
KR20230002706A (en) 2023-01-05
CN115916791A (en) 2023-04-04
PE20230388A1 (en) 2023-03-06
AU2021255488A1 (en) 2022-11-10
DOP2022000221A (en) 2023-01-15
IL297212A (en) 2022-12-01
ECSP22080982A (en) 2023-01-31
TW202202501A (en) 2022-01-16
MX2022012952A (en) 2023-01-11
CA3174316A1 (en) 2021-10-21
AU2021255488B2 (en) 2024-05-30
WO2021211380A1 (en) 2021-10-21
CO2022014882A2 (en) 2022-10-31
EP4136090A1 (en) 2023-02-22
CL2022002849A1 (en) 2023-06-16

Similar Documents

Publication Publication Date Title
TN2019000110A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
PH12018500121A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TN2019000107A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
PH12021500017A1 (en) Pyrazolo [3,4-b]pyridine compounds as inhibitors of tam and met kinases
CR20220520A (en) Crystalline ret inhibitor
MX2022007221A (en) Valproic acid for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation.
MX2022010425A (en) Methods of treating estrogen receptor-associated diseases.
WO2019040106A3 (en) Compounds, salts thereof and their use in the treatment of diseases
IL287032A (en) Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes
IL286636A (en) Compositions and methods for the treatment of kras associated diseases or disorders
MX2019008124A (en) Methods for the treatment of neurological disorders.
MX2020008680A (en) Combination therapy with apilimod and glutamatergic agents.
MX2021007260A (en) Jak1 pathway inhibitors for the treatment of gastrointestinal disease.
ZA202006072B (en) Ret inhibitor for use in treating cancer having a ret alteration
MX2023008968A (en) Cdk2 inhibitors and methods of using the same.
MX2020009942A (en) Compounds and uses thereof.
WO2023081830A3 (en) Compositions and treatments with nirogacestat
CR20210364A (en) Quinoline compounds as inhibitors of tam and met kinases
MX2021002652A (en) Use of casein kinase 1 inhibitors for treating vascular diseases.
NZ772236A (en) Pharmaceutical combination for use in age-related and/or degenerative diseases
MX2021008903A (en) Compounds and uses thereof.
MX2022010456A (en) Heterocyclic compounds for modulating nr2f6.
MX2021003992A (en) Inhibiting fatty acid synthase (fasn).
MX2022001274A (en) Serotonergic agent and 5-ht1a-receptor antagonist.
MX2019012088A (en) Nk1-antagonist combination and method for treating synucleinopathies.